These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15850320)

  • 1. [Assessment of soluble E selectin levels in patients with Graves' disease and thyroid orbitopathy].
    Kulig G; Pilarska K; Kulig J; Robaczyk M; Gromniak E
    Przegl Lek; 2004; 61(12):1314-8. PubMed ID: 15850320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients witt Graves' disease and thyroid associated orbitopathy].
    Kulig G; Pilarska K; Kulig J
    Przegl Lek; 2004; 61(12):1319-24. PubMed ID: 15850321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
    De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter].
    Modelska-Ziółkiewicz A; Gembicki M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):463-8. PubMed ID: 14768174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy.
    Wakelkamp IM; Gerding MN; van der Meer JW; Prummel MF; Wiersinga WM
    Clin Exp Immunol; 2002 Feb; 127(2):316-20. PubMed ID: 11876756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of radioiodine 131I treatment in Graves' disease patients with mild orbitopathy].
    Bałdys-Waligórska A; Stefańska A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
    Przegl Lek; 2009; 66(4):166-9. PubMed ID: 19708504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
    Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
    Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
    Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy].
    Kulig G; Pilarska K; Kulig J; Krzyzanowska-Swiniarska B; Robaczyk M; Baraniak A
    Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The common variants of E-selectin gene in Graves' disease.
    Chen H; Cui B; Wang S; Zhao Z; Sun H; Gu X; Zhao Y; Li X; Ning G
    Genes Immun; 2008 Mar; 9(2):182-6. PubMed ID: 18094708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of surgical treatment in Graves' disease orbitopathy. Is there a correlation between the extent of thyroidectomy and the course of orbithopathy?
    Maurer E; Dănilă R; Dominguez E; Osei-Agymang T; Zielke A; Hassan I
    Chirurgia (Bucur); 2008; 103(3):291-5. PubMed ID: 18717277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy.
    Martins JR; Furlanetto RP; Oliveira LM; Mendes A; Passerotti CC; Chiamolera MI; Rocha AJ; Manso PG; Nader HB; Dietrich CP; Maciel RM
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):726-33. PubMed ID: 15163337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum glycosaminoglycans in Graves' disease patients].
    Winsz-Szczotka KB; Olczyk KZ; Koźma EM; Komosińska-Vassev KB; Wisowski GR; Marcisz C
    Wiad Lek; 2006; 59(1-2):66-71. PubMed ID: 16646296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis--from laboratory parameters to clinical scores.
    Angelova-Fischer I; Hipler UC; Bauer A; Fluhr JW; Tsankov N; Fischer TW; Elsner P
    Br J Dermatol; 2006 Jun; 154(6):1112-7. PubMed ID: 16704642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The assessment of usefulness of humoral markers estimation in patients with autoimmune thyroid diseases].
    Myśliwiec J; Okłota M; Nikołajuk A; Górska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):663-6. PubMed ID: 16498807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pro 12 Ala PPAR gamma gene polymorphism: possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO).
    Alevizaki M; Mantzou E; Cimponeriu A; Saltiki K; Philippou G; Wiersinga W
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):464-8. PubMed ID: 18624999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.